InformationMotolimod (VTX-2337) Motolimod (VTX-2337) is a selective and potent Toll-like receptor 8 (TLR8) agonist with EC50 of 100 nM, > 50-fold selectivity over TLR7. Phase 2.TargetsTLR8 100 nM(EC50)In vitroVTX-2337 stimulates the production of both TNFα with EC50 of 140 nM and IL-12 with EC50 of 120 nM in PBMCs. In monocytes and mDCs, VTX-2337 selectively induces the production of TNFα and IL-12 via NF-κB activation. VTX-2337 also stimulates IFNγ production from NK cells, augments the lytic function of NK cells and enhances ADCC.In vivoIn an ovarian cancer mouse model, TX-2337 enhances the effect of pegylated liposomal doxorubicin (PLD).Cell Research(from reference)Cell lines：PBMCs or purified NK cells Concentrations：~500 nM Incubation Time：48 h. Specification: 0.99 Molecular Formula: C28H34N4O2 Molecular Weight: 458.6 PubChem CID: 16049404 Isomeric SMILES: CCCN(CCC)C(=O)C1=CC2=C(C=C(C=C2)C3=CC=C(C=C3)C(=O)N4CCCC4)N=C(C1)N Related Documents: https://ald-pub-files.oss-cn-shanghai.aliyuncs.com/aladdinsci/pdp/sds/1/M413715-SCI_39009df944d9e733b5a02235c068bcf4.pdf
- UPC:
- 51202800
- Condition:
- New
- Availability:
- 2 weeks
- Weight:
- 0.96 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- M413715-1mg
- CAS:
- 926927-61-9
- Product Size:
- 1mg
- Hazard Statement Codes:
- H302:H315:H319:H335
- Precautionary Statement Codes:
- P261:P305+P351+P338
